Overview

A Trial for Patients With Advanced/Recurrent Endometrial Cancer

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The intent of this protocol is to screen a new agent for activity in patients with advanced or recurrent endometrial carcinoma. This phase II trial is studying how well pemetrexed disodium works in treating patients with advanced or recurrent endometrial carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Gynecologic Oncology Group
Treatments:
Pemetrexed